## EXHIBIT D



## LETTER OF RELIANCE

Mail Stop Hatch-Waxman PTE
Office of Patent Legal Administration
Room MDW 7D55
600 Dulany Street (Madison Building)
Alexandria, VA 22314

Attn: Mary C. Till, Examiner

Office of Patent Legal Administration

Gilead Sciences, Inc., Licensee of the exclusive rights to U.S. Patent No. 5,840,722 ("U.S.'722"), authorizes Abbott Laboratories, Licensor and record-owner of U.S.'722, to rely on the activities of Gilead Sciences, Inc. supporting FDA approval of LETAIRIS™ (ambrisentan) product (5 and 10 mg tablets), for the purpose of obtaining extension of patent term of U.S.'722, as provided under 35 U.S.C. §156(d)(1), 37 C.F.R. §1.730 and MPEP 2752.

Date: 8/2/07

Authorized by Gilead Sciences, Inc.

By:

Richard J. Gorczynski, PhD

SVP, Cardiovascular Therapeutics